Literature DB >> 30482761

Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.

Stefan Willmann1, Liping Zhang2, Hannah Mayer3, Hans-Ulrich Siegmund3, Takahiko Tanigawa4, Masato Kaneko4, Gary Peters5, Jeffrey I Weitz6,7, Scott D Berkowitz8, Rolf Burghaus1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30482761      PMCID： PMC6258927          DOI： 10.1182/bloodadvances.2018027078

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  21 in total

1.  Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.

Authors:  Gregory Y H Lip; Felicita Andreotti; Laurent Fauchier; Kurt Huber; Elaine Hylek; Eve Knight; Deirdre A Lane; Marcel Levi; Francisco Marin; Gualtiero Palareti; Paulus Kirchhof; Jean-Philippe Collet; Andrea Rubboli; Daniela Poli; John Camm
Journal:  Europace       Date:  2011-05       Impact factor: 5.214

Review 2.  Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants.

Authors:  D Garcia; Y C Barrett; E Ramacciotti; J I Weitz
Journal:  J Thromb Haemost       Date:  2013-02       Impact factor: 5.824

3.  Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.

Authors:  R Kreutz; P B Persson; D Kubitza; K Thelen; S Heitmeier; S Schwers; M Becka; M Hemmrich
Journal:  J Thromb Haemost       Date:  2017-09-14       Impact factor: 5.824

4.  The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.

Authors:  Hugo Ten Cate; Anthonie W A Lensing; Jeffrey I Weitz; Saskia Middeldorp; Jan Beyer-Westendorf; Dagmar Kubitza; Timothey Brighton; Gary E Raskob; Patrick Mismetti; Paolo Prandoni; Martin Gebel; Martin H Prins
Journal:  Thromb Res       Date:  2018-08-15       Impact factor: 3.944

5.  Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

Authors:  Wolfgang Mueck; Anthonie W A Lensing; Giancarlo Agnelli; Hervé Decousus; Paolo Prandoni; Frank Misselwitz
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

6.  Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

Authors:  Wolfgang Mueck; Bengt I Eriksson; Kenneth A Bauer; Lars Borris; Ola E Dahl; William D Fisher; Michael Gent; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Louis M Kwong; Frank Misselwitz; Alexander G G Turpie
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.

Authors:  I G Girgis; M R Patel; G R Peters; K T Moore; K W Mahaffey; C C Nessel; J L Halperin; R M Califf; K A A Fox; R C Becker
Journal:  J Clin Pharmacol       Date:  2014-03-26       Impact factor: 3.126

8.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

Review 9.  Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.

Authors:  Wolfgang Mueck; Jan Stampfuss; Dagmar Kubitza; Michael Becka
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

10.  Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations.

Authors:  Stefan Willmann; Liping Zhang; Matthias Frede; Dagmar Kubitza; Wolfgang Mueck; Stephan Schmidt; Alexander Solms; Xiaoyu Yan; Dirk Garmann
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.